legal analysis:

daboshu (cindilizumab), the PD1 inhibitor of Cinda Bio, is included in the medical insurance catalogue, and it is the only PD1 monoclonal antibody drug listed in the national medical insurance catalogue at present, and the reimbursement will be implemented from January 22.

after the price reduction of medical insurance, a bottle of daboshu (cindilizumab) is 2843 yuan. According to the medical insurance policy, Class B drugs can be paid according to the basic medical insurance by setting a certain proportion of individual self-payment. Take the medical insurance for employees in Guangzhou as an example, it is required to pay 284.3 yuan at the expense of 1% first, 511.74 yuan after the remaining 9% expenses are reimbursed according to the proportion of 8%, and 796 yuan each. According to the reimbursement policy of Jiangsu Province, the reimbursement by medical insurance is about 7%, and the individual pays 3%, which is about 85. For specific medical insurance policies and reimbursement benefits, please consult your local medical insurance department.

Legal basis:

Article 28 of the Social Insurance Law of the People's Republic of China

Medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facilities standards and emergency and rescue shall be paid from the basic medical insurance fund in accordance with state regulations.

article 29 the part of the medical expenses of the insured that should be paid by the basic medical insurance fund shall be directly settled by the social insurance agency, medical institutions and pharmaceutical trading units. The administrative department of social insurance and the administrative department of health shall establish a settlement system for medical expenses in different places, so as to facilitate the insured to enjoy the basic medical insurance benefits.